Nevirapina Mylan (Nevirapine)

Nevirapine, the active ingredient in Nevirapina Mylan, is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral dosage form for oral use. It is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents, targeting adults and children who require viral suppression.

GNH USA supplies Nevirapina Mylan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is used in antiretroviral regimens to control HIV-1 infection across different patient groups.

- Adult HIV-1 infection: part of combination therapy to achieve and maintain viral load suppression. - Pediatric HIV-1 infection: combined with other agents to control viral replication in children. - Treatment‑experienced HIV-1 infection: added to regimens when resistance to other drugs is present.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal upset. - Fatigue: feeling of tiredness or weakness. - Headache: transient head discomfort.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatic failure: signs of liver toxicity such as jaundice. - Hypersensitivity reactions: including fever, eosinophilia, or organ involvement. - Neutropenia: significant reduction in white blood cells.

Before initiating therapy, several safety considerations should be observed.

- Liver function monitoring: assess baseline enzymes and repeat periodically. - Rash surveillance: discontinue promptly if severe skin reactions develop. - Hypersensitivity awareness: avoid in patients with known nevirapine allergy. - Pregnancy caution: use only when benefits outweigh risks, as classified Category B. - Hepatic impairment adjustment: dose may need modification in severe liver disease. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nevirapine can interact with several medications, influencing efficacy or safety.

Major Interactions (Avoid): - Rifampin: induces metabolism, reducing nevirapine levels. - St. John’s wort: strong enzyme inducer, may lower drug exposure. - Protease inhibitors (e.g., ritonavir): can increase nevirapine concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Efavirenz: may require dose adjustment due to shared metabolic pathways. - Methadone: nevirapine can decrease methadone levels, potentially precipitating withdrawal.